China in-licensing play LianBio follows $310M crossover round with broad Pfizer deal

Pfizer’s deal with LianBio will provide the Perceptive-backed, cross-border start-up with a commercial infrastructure in China, while giving the pharma a drug hunter and development partner led by veteran China biotech executives Bing Li and Debra Yu that can co-develop best-in-class products to freshen its portfolio in the country.

Pfizer Inc. (NYSE:PFE), which participated in LianBio’s $310 million crossover round in October, will contribute up to $70 million in non-dilutive capital toward in-licensing, co-development and in-kind support for marketing, development and regulatory activities. ...